We are delighted to lead a CHF 27M funding round for Aktiia (RAC III), the healthtech company revolutionizing hypertension management. Joining us in this round are Khosla Ventures, Molten, Translink Capital, Verve, and 415 Capital.
Alongside this funding announcement, Aktiia has appointed Daniel Graf as their new President and Board Member. A long-time friend and collaborator of Redalpine, we are proud to have facilitated this key move. With an impressive background in entrepreneurship and product innovation from his roles at Google, Uber, and X, Daniel’s expertise will be instrumental in Aktiia’s expansion and product development plans.
Hypertension affects over 1.4 billion people worldwide, yet sufferers have lacked access to real-time data and insights into their condition, which, if left uncontrolled, can lead to serious complications such as heart attacks, strokes, and kidney problems.
Aktiia’s wrist-worn 24/7 optical blood pressure monitoring device is a world-first, providing wearers with personalized, continuous, medical-grade data and insights, thereby revolutionizing hypertension management. Built on over 20 years of research, Aktiia's CE-certified device is currently available in seven European regions and recognized as a medical instrument in 44 countries globally. This latest investment will accelerate Aktiia’s mission in AI-driven advancements in high blood pressure management.
Speaking about his new role and the future of the company, Daniel Graf said, "Aktiia's commitment to transforming blood pressure monitoring aligns perfectly with my passion for leveraging technology in healthcare. I am excited to join this talented team and contribute to a future where hypertension management is proactive, data-driven, personalized, and effective."
"We are proud to have Daniel join our board and executive team," added Mattia Bertschi, CEO of Aktiia. "His expertise in scaling innovative technologies will be invaluable as we continue to expand our reach and impact in the global healthcare market. The infusion of new capital is a testament to the confidence our investors have in our mission and technology, and we are excited to accelerate our efforts to revolutionize hypertension management."
We are excited to empower GameChangers in healthcare and reaffirm our commitment to Aktiia’s mission by providing medical and industry knowledge, along with strategic advice to the team. Congratulations to Mattia Bertschi and Josep Solà!